← SynDRA
AUMOLERTINIB
SynDRA canonical compound SYN0040223 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
| Primary target(s) | EGFR |
| Mechanism of action | egfr inhibitor |
| Indication | non-small cell lung cancer (nsclc) |
| Disease area | oncology |
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- Almonertinib
- Ameile
- Amerol
- Egfr t790m inhibitor hs-10296
- HS-10296
- EQ-143
- EQ143
- HS-10206
- Egfr T790M inhibitor HS-10296
- N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
- UNII-T4RS462G19
- SCHEMBL17683063
- GTPL11136
- T4RS462G19
- EX-A3721
- HS 10296 [WHO-DD]
- s8817
- HS10296
- example 26 [WO2016054987A1]
- HY-112823
- CS-0066162
- 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-
- C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC
- N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
- Hs 10296
- RefChem:115556
- EGFR Tyrosine Kinase Inhibitor HS-10296
- HS-10297
- Aumolertinib [USAN]
- MFCD32173681
- Almonertinib (Standard)
- Aumolertinib [WHO-DD]
- Aumolertinib (USAN/INN)
- AUMOLERTINIB [INN]
- orb1301771
- SCHEMBL29389482
- C30H35N7O2
- GLXC-26972
- HMS5086I13
Look up AUMOLERTINIB in the interactive SynDRA portal →